胆道系统肿瘤靶向联合免疫治疗研究进展

Recent advances in combined application of targeted therapy and immunotherapy in biliary tract neoplasms

胆道系统肿瘤(BTN)是起源于胆道系统上皮细胞、高度异质性的恶性肿瘤,分为胆囊和胆管来源。目前,包括化疗及分子靶向治疗在内的系统治疗手段有限,预后不理想。近年来,随着对BTN研究的逐渐深入,有关靶向联合免疫治疗方案的基础和临床研究蓬勃发展,并得出令人振奋的研究结果,为进一步改善BTN预后带来希望。在剖析BTN的靶向或免疫单药治疗疗效欠佳的原因的基础上,讨论靶向联合免疫治疗的优势及目前基础、临床研究的进展,将会为进一步联合治疗方案的提出和选择提供新思路。

Biliary tract neoplasms(BTN) are a heterogeneous group of malignancies arising from epithelial along the biliary tree including the bile ducts and gallbladder. At present, the systemic therapies including chemotherapy and molecular targeted therapy are limited, and the prognosis is not ideal. In recent years, with the in-depth study on BTN, basic and clinical research on combined application of targeted therapy and immunotherapy are developing vigorously and get encouraging results, which brings great hope into how to further improve the prognosis of BTN. Thus, analyzing the main reasons of relatively bad efficacy using targeted or immune monotherapy seperately, on the basis of which reviewing and discussing potential advantages of combined therapy, and summarizing the current status and research progress of basic and clinical studies based on combined application of targeted therapy and immunotherapy for BTN systematically, may provide new ideas and references for more alternative choices of combined treatment for BTN.